SELLAS Life Sciences Group, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from SELLAS Life Sciences Group, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 87% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 629% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 87% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +274%In 3 years sales changed by -100% while total assets changed by +274%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-52.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 74% of Healthcare companies in United States.
Cash Cushion Ratio
+3%Cash, after subtracting all debt, equals 3% of its market value (net cash).
Lower than 62% of Healthcare companies in United States.
Tangible Assets Ratio
98%Of every $100 the company owns, $98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 82% of Healthcare companies in United States.
Tangible Net Worth Ratio
97%Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 87% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
SELLAS Life Sciences Group, Inc. made a loss over the last year. SELLAS Life Sciences Group, Inc. owes $0.05 for every $1 it owns. SELLAS Life Sciences Group, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSELLAS Life Sciences Group, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
16.93The share price is 16.93 times SELLAS Life Sciences Group, Inc.'s book value per share, higher than 92% of Healthcare companies in United States.
Market cap
$2.3 BThe total market value of all of SELLAS Life Sciences Group, Inc.'s shares at today's price (share price × number of shares), larger than 77% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$138 MWhat SELLAS Life Sciences Group, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.68Net worth divided by the number of shares. The share price of $11.54 is 16.9 times this, which is the P/B above.
Return on equity (ROE)
-39.6%SELLAS Life Sciences Group, Inc. lost 39.6% of its shareholders' money over the last year, higher than 55% of Healthcare companies in United States.
Owes vs Owns
0.05×SELLAS Life Sciences Group, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Dividend yield
NoneSELLAS Life Sciences Group, Inc. does not currently pay a dividend.
Profit growth
LossSELLAS Life Sciences Group, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashSELLAS Life Sciences Group, Inc. held $71 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For SELLAS Life Sciences Group, Inc.: $2.3 B ÷ $138 M (30 Jun 2026) = 16.9.
What is SELLAS Life Sciences Group, Inc.'s return on equity?
SELLAS Life Sciences Group, Inc. lost 39.6% of its shareholders' money over the last year, higher than 55% of Healthcare companies in United States.
How much does SELLAS Life Sciences Group, Inc. owe compared with what it owns?
SELLAS Life Sciences Group, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Does SELLAS Life Sciences Group, Inc. pay a dividend?
No. SELLAS Life Sciences Group, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.